Agilent Technologies Inc (NYSE:A) And BioTek In Partnership Aimed At Creating A Metabolic Analysis And Imaging Platform


Agilent Technologies Inc (NYSE:A) has a jointly announced a strategic collaboration with Biotek Instruments, through which the two will work towards creating a new solution that will leverage imaging technologies and metabolic analysis.

The solution involves a combination of the BioTek Cytation 1 Cell Imaging Multi-Mode Reader and the BioTek Cytation 1 Cell Imaging Multi-Mode Reader. The resulting optimized solution creates a standardized approach for through which XF data sets can be compared while also facilitating other advantages such as improved assay workflow. It also allows the application of normalization values to Seahorse XF measurements and the embedding of images into the WAVE software.

“The collaboration between Agilent and BioTek was a natural extension of our shared goal to advance scientific discovery through technological innovation,” stated Biotek’s Global Marketing and Sales Director, Gary Barush.

Barush also added that the combination of Biotek’s Cytation 1 Cell Imaging Multi-Mode Reader and the automated XFe Analyzers from Agilent represents a big opportunity for cell researchers. He stated that the collaboration will allow researchers to analyze and normalize samples so that they will be able to come up with answers to challenging questions involving cellular metabolism.

David Ferrick, the Director of the Cell Analysis Division at Agilent stated that the company’s customers have been requesting for an optimized solution for verifying assay results and also for facilitating more meaningful data comparisons. The integrated solution as part of the collaborative efforts should thus provide customers with the ability to carry out proper data comparison.

The integration of the Agilent Seahorse XF WAVE software with a high level of imagery takes the data to a whole different level. It makes it possible for researchers to toggle between fluorescence images, brightfield images, and XF data. This provides a guide on how to enhance the reproducibility of the XF assays while also improving the reproducibility. The use of a normalization value that is based on cell count brings more ease to the interpretation of Seahorse XF data. The two firms are expected to jointly manage the integrated solution whose scheduled release is this month.

Agilent Technologies stock closed Friday’s trading session at $63.65.


Please enter your comment!
Please enter your name here